Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06060405 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Durvalumab and Oleclumab in Resectable PDAC

Study acronym: DORA
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv3
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Oct 30, 2023 to Nov 29, 2023 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Oct 30, 2023 to Nov 29, 2023
    • Site details revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multi-site Canadian, window of opportunity study to evaluate the immune activity of durvalumab and oleclumab in resectable pancreatic ductal adenocarcinoma (PDAC) when given prior to surgery.
Trial Details
NCT Number NCT06060405
Lead Sponsor University Health Network, Toronto
Conditions Pancreatic Ductal Adenocarcinoma
Enrollment 22 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov